The bile duct cancer story is pretty interesting. If I’ve understood it correctly FDA have said to OSL they’ll consider approval under HDE path for the distal BD cancer variety based on LAPC ie Panco trial data? Unusual approach, FDA would be approving a device for a cancer for which it has no data based on its usage in another similar cancer in which its efficacy is unproven. Interesting! Looking forward to seeing how that goes.
as for the intrahepatic variety that OSL has said they’ll look at later they’d possibly be going up against Sirtex which is running phase 3 trial to complete with results next year apparently.
Investor Presentation, page-127
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
-0.001(9.09%) |
Mkt cap ! $16.66M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.6¢ | 0.5¢ | $62.00K | 12.03M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 6487586 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 24090459 | 22 |
View Market Depth
| Last trade - 16.10pm 28/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.5¢ |
Change
-0.001 ( 9.09 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.5¢ | 0.5¢ | 6680000 | ||
| Last updated 15.48pm 28/05/2024 ? | |||||
| OSL (ASX) Chart |